- $314.08m
- $175.27m
- 54
- 23
- 53
- 39
Annual income statement for Korro Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 28.9 | 37 | 14.1 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 12.9 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 49.6 | 64.5 | 98.1 | 83 | 84.5 |
Operating Profit | -20.7 | -27.6 | -84 | -83 | -84.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -18.7 | -26.5 | -84.7 | -81.6 | -81.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -18.7 | -26.5 | -84.7 | -81.6 | -81.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -18.7 | -26.5 | -84.7 | -81.6 | -81.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -19.8 | -26.5 | -84.7 | -81.6 | -81.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -31.8 | -41.1 | -123 | -116 | -53.1 |